Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
Model scores of the 29,894 trials active now.
Model score 7% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Completed on 2020-04-30, after 2016-07-31 start.
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-04-30. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Accepts healthy volunteers: Yes (lowers risk) · Who can join
-
Wording of the registration (title, summary, criteria) (lowers risk) · Wording
Phrases that raised it: paineffectsanalgesicblind placeboplacebo controlled
Phrases that lowered it: healthyvolunteerscurrentdrugsubjects who -
Phase: 1/2 (raises risk) · Design
-
Drug's FAERS reports marked serious: 40.4% (lowers risk) · Drug's FDA history
-
Minimum age: 21 (lowers risk) · Who can join
-
Sponsor's past termination rate: 7.9% (raises risk) · Sponsor's track record
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Design: single group (raises risk) · Design
-
Trials the sponsor started in the prior 2 years: 79 (lowers risk) · Sponsor's track record
-
Disease area, cancer: No (lowers risk) · Disease area
-
Has a data monitoring committee: No (lowers risk) · Design
-
Drug's FAERS reports with a death: 3.5% (lowers risk) · Drug's FDA history
-
Sponsor's past trials: 265 (lowers risk) · Sponsor's track record
-
Maximum age: 50 (lowers risk) · Who can join
-
Blinding: double (raises risk) · Design
-
Collaborators: 1 (raises risk) · Design
-
Number of arms: 2 (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1/2 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- single group (typical: parallel)
- Primary purpose
- basic science (typical: treatment)
- Blinding
- double (typical: none)
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 1 (typical: 0)
- Keywords listed
- 0 (typical: 1)
Who can join
- Minimum age
- 21 (typical: 18)
- Maximum age
- 50 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- Yes (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 265 (typical: 32)
- Sponsor's past termination rate
- 7.9% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 79 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 1
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 57 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 42 (typical: 412.5)
- Drug's FAERS reports marked serious
- 40.4% (typical: 85.6%)
- Drug's FAERS reports with a death
- 3.5% (typical: 15.9%)
Disease area and drugs
- Disease areas
- none of the 14 tracked areas
- Drugs matched to FDA substances
- cannabidiol
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Enhancing Medication-based Analgesia in Humans- STUDY 2 NCT04036968 · started 2020 · scored riskier than 29% of active trials completed
- CBD for Chronic Radicular Pain on Chronic Opioid Therapy (COT) NCT04760613 · started 2022 · scored riskier than 36% of active trials completed
- A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users NCT05407285 · started 2022 · scored riskier than 6% of active trials completed
- Reducing Pain and Opioid Use With CBD NCT05299944 · started 2022 · scored riskier than 38% of active trials completed
- Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana NCT01844687 · started 2013 · scored riskier than 11% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.